Stroke, Vol 22, 242-246, Copyright © 1991 by American Heart Association
L Kaminow and J Bevan
We assessed the value of pretreatment with clentiazem (8- chlorodiltiazem),
a diltiazem derivative with cerebroselective properties, on the
consequences of surgical occlusion of the middle cerebral artery via a
transorbital approach in 38 rabbits. Nineteen rabbits received 1.7 (n = 5),
5 (n = 8), or 15 (n = 6) mg/kg clentiazem orally four times a day for 24
hours before and 48 hours after occlusion. Upon sacrifice, a segment of the
right middle cerebral artery distal to the occlusion and a corresponding
segment from the nonoccluded left middle cerebral artery were mounted on
myographs for in vitro study of their reactivity to histamine,
acetylcholine, serotonin, norepinephrine, and electrical stimulation of
intramural sympathetic nerves. Morphometric measurements of 2,3,5-
triphenyltetrazolium chloride-stained brain slices permitted us to estimate
infarct volume. Pretreatment with 1.7, 5, and 15 mg/kg clentiazem
significantly reduced infarct volume (p less than 0.05, p less than 0.01,
and p less than 0.01, respectively). Mean infarct volume of the 15
mg/kg-treated group was only 4% that of the untreated group. There were no
postoperative deaths in any treated group compared with a death rate of 36%
in the untreated group. Mean values for vascular smooth muscle
contractility to histamine and relaxation to acetylcholine were
significantly enhanced in vessels from treated rabbits. These studies
indicate that pretreatment with clentiazem offers cerebral protection and
significantly reduces infarct volume as well as arterial wall damage beyond
the occlusion.
ARTICLES
Clentiazem reduces infarct size in rabbit middle cerebral artery occlusion
Department of Neurosurgery, Vermont, College of Medicine, Burlington.
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1991 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |